-
Norihisa Miyake
Medical Information Department and Planning & Investigation Department,Nippon Chemiphar Co.,Ltd.,2-3,2-chome,Iwamoto-cho Chiyoda-ku,Tokyo 101-8678,Japan Department of Pharmacology and Toxicology,Cancer Research Institute,Tohoku Pharmaceutical University,4-4-1 Komatsushima,Aoba-ku,Sendai 981-8558,Japan
-
Ryousuke Fujita
Department of Pharmacology and Toxicology,Cancer Research Institute,Tohoku Pharmaceutical University,4-4-1 Komatsushima,Aoba-ku,Sendai 981-8558,Japan
-
Masaaki Ishikawa
Department of Pharmacology and Toxicology,Cancer Research Institute,Tohoku Pharmaceutical University,4-4-1 Komatsushima,Aoba-ku,Sendai 981-8558,Japan
-
Motoaki Takayanagi
Department of Pharmacology and Toxicology,Cancer Research Institute,Tohoku Pharmaceutical University,4-4-1 Komatsushima,Aoba-ku,Sendai 981-8558,Japan
-
Yoshio Takayanagi
Department of Pharmacology and Toxicology,Cancer Research Institute,Tohoku Pharmaceutical University,4-4-1 Komatsushima,Aoba-ku,Sendai 981-8558,Japan
-
Ken-ichi Sasaki
Department of Pharmacology and Toxicology,Cancer Research Institute,Tohoku Pharmaceutical University,4-4-1 Komatsushima,Aoba-ku,Sendai 981-8558,Japan
